Janney Montgomery Scott’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.6M Buy
397,760
+65,757
+20% +$3.12M 0.04% 439
2025
Q4
$16.9M Buy
332,003
+172,075
+108% +$8.8M 0.04% 423
2025
Q3
$8.87M Buy
159,928
+3,811
+2% +$223K 0.02% 661
2025
Q2
$10.8M Buy
156,117
+1,699
+1% +$116K 0.03% 537
2025
Q1
$10.7M Sell
154,418
-40,766
-21% -$3.37M 0.03% 509
2024
Q4
$16.8M Sell
195,184
-69,383
-26% -$7.5M 0.05% 387
2024
Q3
$31.5M Sell
264,567
-4,017
-1% -$536K 0.09% 231
2024
Q2
$38.3M Sell
268,584
-63,167
-19% -$8.37M 0.12% 175
2024
Q1
$42.6M Buy
331,751
+26,573
+9% +$3.16M 0.13% 165
2023
Q4
$31.6M Buy
305,178
+15,392
+5% +$1.52M 0.1% 197
2023
Q3
$26.4M Buy
289,786
+15,290
+6% +$1.35M 0.1% 200
2023
Q2
$22.2M Buy
274,496
+24,880
+10% +$2.03M 0.08% 237
2023
Q1
$19.9M Sell
249,616
-26,562
-10% -$1.88M 0.08% 233
2022
Q4
$18.7M Buy
276,178
+28,814
+12% +$1.69M 0.07% 253
2022
Q3
$12.3M Buy
247,364
+1,748
+0.7% +$93.6K 0.05% 324
2022
Q2
$13.5M Sell
245,616
-6,394
-3% -$355K 0.06% 281
2022
Q1
$14M Buy
252,010
+3,678
+1% +$189K 0.06% 301
2021
Q4
$13.9M Sell
248,332
-37,810
-13% -$2.05M 0.05% 310
2021
Q3
$13.7M Buy
286,142
+14,178
+5% +$685K 0.06% 291
2021
Q2
$11.4M Buy
271,964
+9,690
+4% +$376K 0.05% 334
2021
Q1
$8.84M Sell
262,274
-16,740
-6% -$596K 0.04% 360
2020
Q4
$9.74M Buy
279,014
+34,352
+14% +$1.19M 0.05% 335
2020
Q3
$8.49M Buy
244,662
+158,524
+184% +$5.28M 0.05% 332
2020
Q2
$2.82M Sell
86,138
-3,780
-4% -$121K 0.02% 640
2020
Q1
$2.71M Sell
89,918
-80,626
-47% -$2.4M 0.02% 585
2019
Q4
$4.94M Buy
170,544
+19,258
+13% +$533K 0.03% 466
2019
Q3
$3.91M Buy
151,286
+72,662
+92% +$1.84M 0.03% 518
2019
Q2
$2.01M Sell
78,624
-5,932
-7% -$147K 0.02% 737
2019
Q1
$2.21M Sell
84,556
-16,442
-16% -$404K 0.02% 664
2018
Q4
$2.33M Buy
100,998
+11,646
+13% +$259K 0.02% 588
2018
Q3
$2.11M Buy
89,352
+1,500
+2% +$36.6K 0.02% 678
2018
Q2
$2.03M Sell
87,852
-5,614
-6% -$133K 0.02% 667
2018
Q1
$2.3M Buy
93,466
+5,232
+6% +$137K 0.02% 596
2017
Q4
$2.37M Buy
88,234
+9,218
+12% +$234K 0.02% 592
2017
Q3
$1.9M Sell
79,016
-7,312
-8% -$165K 0.02% 635
2017
Q2
$1.85M Buy
86,328
+29,998
+53% +$605K 0.02% 609
2017
Q1
$965K Buy
56,330
+6,238
+12% +$109K 0.01% 852
2016
Q4
$898K Sell
50,092
-56,380
-53% -$1.02M 0.01% 821
2016
Q3
$2.21M Sell
106,472
-66,508
-38% -$1.65M 0.04% 409
2016
Q2
$4.65M Buy
172,980
+85,632
+98% +$2.35M 0.09% 175
2016
Q1
$2.37M Buy
87,348
+5,510
+7% +$148K 0.06% 289
2015
Q4
$2.38M Sell
81,838
-4,600
-5% -$127K 0.06% 300
2015
Q3
$2.34M Buy
86,438
+6,294
+8% +$178K 0.07% 304
2015
Q2
$2.19M Sell
80,144
-768
-0.9% -$21.6K 0.05% 463
2015
Q1
$2.16M Sell
80,912
-6,484
-7% -$149K 0.04% 539
2014
Q4
$1.85M Sell
87,396
-96
-0.1% -$2.14K 0.04% 584
2014
Q3
$2.08M Buy
87,492
+19,160
+28% +$441K 0.04% 511
2014
Q2
$1.58M Buy
68,332
+5,372
+9% +$119K 0.03% 607
2014
Q1
$1.44M Buy
62,960
+11,730
+23% +$250K 0.03% 592
2013
Q4
$947K Buy
51,230
+16,900
+49% +$295K 0.03% 754
2013
Q3
$581K Buy
+34,330
New +$577K 0.02% 912

Other funds holding NVO

Janney Montgomery Scott's NVO Position: Q1 2026 in Review

Janney Montgomery Scott increased its Novo Nordisk (NVO) stake by 20% in Q1 2026, buying an estimated $3.12M and bringing the position to 397,760 shares worth $14.6M. The position accounts for 0.04% of the portfolio, ranked #439.

Janney Montgomery Scott first reported a position in NVO in Q3 2013 and has held it in 51 quarters since. The position peaked at $42.6M in Q1 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Janney Montgomery Scott held 397,760 shares of Novo Nordisk worth $14.6M as of Q1 2026.
  • Janney Montgomery Scott bought 65,757 Novo Nordisk shares in Q1 2026, an estimated $3.12M.
  • Novo Nordisk made up 0.04% of Janney Montgomery Scott's portfolio in Q1 2026, its #439 holding.
  • Janney Montgomery Scott first reported a position in Novo Nordisk in Q3 2013 and has held it in 51 quarters since.
  • Janney Montgomery Scott's Novo Nordisk position peaked at $42.6M in Q1 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Janney Montgomery Scott's 13F filing for Q1 2026, filed 22 Apr 2026.